RT Journal Article
T1 PDGF Restores the Defective Phenotype of Adipose-Derived Mesenchymal Stromal Cells from Diabetic Patients.
A1 Capilla-González, Vivian
A1 López-Beas, Javier
A1 Escacena, Natalia
A1 Aguilera, Yolanda
A1 de la Cuesta, Antonio
A1 Ruiz-Salmerón, Rafael
A1 Martín, Franz
A1 Hmadcha, Abdelkrim
A1 Soria, Bernat
K1 PDGF
K1 adipose-derived mesenchymal stromal cells
K1 critical limb ischemia
K1 diabetes
K1 homing
K1 migration
K1 proliferation
K1 thrombotic state
AB Diabetes is a chronic metabolic disorder that affects 415 million people worldwide. This pathology is often associated with long-term complications, such as critical limb ischemia (CLI), which increases the risk of limb loss and mortality. Mesenchymal stromal cells (MSCs) represent a promising option for the treatment of diabetes complications. Although MSCs are widely used in autologous cell-based therapy, their effects may be influenced by the constant crosstalk between the graft and the host, which could affect the MSC fate potential. In this context, we previously reported that MSCs derived from diabetic patients with CLI have a defective phenotype that manifests as reduced fibrinolytic activity, thereby enhancing the thrombotic risk and compromising patient safety. Here, we found that MSCs derived from diabetic patients with CLI not only exhibit a prothrombotic profile but also have altered multi-differentiation potential, reduced proliferation, and inhibited migration and homing to sites of inflammation. We further demonstrated that this aberrant cell phenotype is reversed by the platelet-derived growth factor (PDGF) BB, indicating that PDGF signaling is a key regulator of MSC functionality. These findings provide an attractive approach to improve the therapeutic efficacy of MSCs in autologous therapy for diabetic patients.
YR 2018
FD 2018-08-16
LK http://hdl.handle.net/10668/12922
UL http://hdl.handle.net/10668/12922
LA en
DS RISalud
RD Apr 5, 2025